PubMed Health⌕ Search

PubMed · 9153718

Epilepsy management: the general practitioner's perspective.

Abstract

The opinions of general practitioners are considered important in the management of people with epilepsy. As part of an evaluation of the Comprehensive Epilepsy Service at The Queen Elizabeth Hospital in South Australia, 120 general practitioners were surveyed about their opinions of the Service and epilepsy issues using self-administered questionnaires. This enabled their opinions about the Service and epilepsy management to be elicited for future planning of effective service provision. The results of the evaluation showed that the Service needed to have a higher profile in the community regarding its existence and role. GPs considered they should manage the care of patients with epilepsy but a cooperative approach between GPs and the Service was important for successful management of difficult cases. Education about epilepsy for the patient and GP was also considered to be important for successful service provision. The GP's involvement in evaluation is essential for influencing the way in which health care services are delivered with regard to availability and accessibility for both themselves and their patients and should be encouraged to ensure effective epilepsy patient management.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A K Averis. 1997. Epilepsy management: the general practitioner's perspective.. https://doi.org/10.1016/s1059-1311(97)80059-3

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor.

Medical therapy for essential tremor (ET), a common movement disorder, is often inadequate. We performed a double-blind placebo-controlled randomized trial to evaluate the efficacy and tolerability of zonisamide (ZNS), an antiepileptic agent, in treating ET. Twenty patients (mean age, 60 +/- 15 years) with ET were randomized to receive ZNS or placebo. ZNS was initiated at a dosage of 100 mg/day and escalated to 200 mg/day at day 14. Patients were evaluated by accelerometry and the Fahn-Tolosa-Marin (FTM) rating scale at baseline and days 14 and 28, as well as the Clinical Global Impression (CGI-C) scale at day 28. At endpoint, subjects assigned to ZNS were taking a mean dosage of 160 +/- 50 mg/day. There were no significant improvements in the FTM total score or its subsections. Tremor amplitude as assessed by accelerometry significantly improved in the ZNS group compared to the placebo group at endpoint relative to baseline (-0.50 +/- 0.72 vs. 0.30 +/- 0.79 m/s(2); P = 0.03). On the CGI-C, 60% (n = 6) of patients in the ZNS group felt that their tremor was unchanged, while the remaining patients felt that their tremor was "minimally improved." Thirty percent (n = 3) of patients taking ZNS discontinued the study due to side effects (fatigue, headache, paresthesias) while taking 100 mg per day. ZNS did not provide significant improvements in clinical rating scales at study endpoint compared to placebo and was only modestly well tolerated. ZNS was effective in reducing tremor amplitude as measured by accelerometry.

Anticonvulsants↗